PROCEPT BioRobotics (PRCT) Projected to Release Earnings on Wednesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.3895) per share and revenue of $100.52 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. The company’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.35) EPS. On average, analysts expect PROCEPT BioRobotics to post ($1.67) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

PROCEPT BioRobotics Trading Down 0.2%

PROCEPT BioRobotics stock opened at $19.80 on Wednesday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -10.21 and a beta of 0.92. The stock has a fifty day simple moving average of $19.49 and a two-hundred day simple moving average of $23.58. PROCEPT BioRobotics has a 12 month low of $16.67 and a 12 month high of $38.11.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Larry Wood bought 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 1,043 shares of company stock valued at $21,851 in the last 90 days. Company insiders own 4.00% of the company’s stock.

Analyst Ratings Changes

PRCT has been the topic of a number of research analyst reports. Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, October 15th. Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Piper Sandler upgraded shares of PROCEPT BioRobotics to a “strong-buy” rating in a research note on Friday, October 16th. Finally, Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Three analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.50.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.